Quantcast
Last updated on April 21, 2014 at 5:21 EDT

Latest Lenalidomide Stories

2013-10-01 23:03:17

In-demand research report “Treating Refractory Hematological Malignancies - Multiple Myeloma (MM): New Treatment Options Driving In-Licensing and M&A” drawn up by MP Advisors has been recently published by Market Publishers Ltd. London,UK (PRWEB) October 01, 2013 Targeting unmet needs in treating hematological malignances through the development of innovative drugs has witnessed considerable achievements recently. Over the past 10 years, proteasome inhibitor Velcade (Bortezomib)...

2013-09-26 12:30:02

John Theurer Cancer Center Chairman and Lymphoma Chief Andre Goy, M.D., M.S., Continues to Lead Advances in MCL Research and Treatment HACKENSACK, N.J., Sept. 26, 2013 /PRNewswire/ -- Andre Goy, M.D., M.S., Chairman and Director of John Theurer Cancer Center and Chief of the Lymphoma Program, has just published two important papers in relapsed/refractory mantle-cell lymphoma (MCL) in the Journal of Clinical Oncology and New England Journal of Medicine. MCL is a difficult subtype...

2013-08-20 08:31:08

STOCKHOLM, August 20, 2013 /PRNewswire/ -- Oncopeptides AB, a company working to enhance oncology therapies, today announced that the first patient has been dosed as part of a Phase II study in multiple myeloma patients with its drug candidate melflufen (previously called J1). (Logo: http://photos.prnewswire.com/prnh/20130521/613959 ) The trial is an open-label Phase II study designed to determine the level of efficacy of melflufen in combination with...

2013-07-01 12:28:33

WHITE PLAINS, N.Y., July 1, 2013 /PRNewswire/ -- The Leukemia & Lymphoma Society (LLS) today announced a collaboration with Johns Hopkins University School of Medicine to advance a novel adoptive immunotherapy for patients with poor prognosis myeloma, a blood cancer. The approach shows promise for patients with other blood cancers as well. Under the leadership of Ivan Borrello, M.D., Johns Hopkins Kimmel Cancer Center, a team of researchers is testing a method using...

2013-06-20 00:21:44

SUNNYVALE, Calif., June 19, 2013 /PRNewswire/ -- Pharmacyclics, Inc. (the "Company") (Nasdaq: PCYC) today announced that The New England Journal of Medicine (NEJM) published results of a Phase 2 study evaluating the investigational oral Bruton's tyrosine kinase (BTK) inhibitor ibrutinib in patients with relapsed/refractory mantle cell lymphoma (MCL) online. These data suggested ibrutinib may be effective and generally well-tolerated in patients with relapsed/refractory MCL. Results of a...

2013-06-17 08:28:07

BOULDER, Colo., June 17, 2013 /PRNewswire/ -- Array BioPharma Inc. (NASDAQ: ARRY) today announced that interim results from an ongoing ARRY-520 clinical trial in multiple myeloma (MM) were presented at the 2013 Congress of the European Hematology Association in Stockholm, Sweden. Also at the meeting, Array presented updated information on a potential patient selection marker for ARRY-520. ARRY-520 is a highly selective, targeted inhibitor of KSP with a mechanism of action distinct...

2013-06-05 16:24:36

WHITE PLAINS, N.Y., June 5, 2013 /PRNewswire/ -- Today's U.S. Food and Drug Administration (FDA) approval of lenalidomide (Revlimid®) to treat patients with mantle cell lymphoma (MCL) is encouraging news for these patients. "Despite advances in treatment, most mantle cell lymphoma patients relapse over time. So, lenalidomide is a welcome effective treatment option for these patients," said Clare Karten, senior director of mission education for The Leukemia & Lymphoma Society (LLS)....

2013-05-15 20:23:38

Enrollment in Phase 1 Clinical Trials of ABT-199 in Chronic Lymphocytic Leukemia Continues NORTH CHICAGO, Ill., May 15, 2013 /PRNewswire/ -- AbbVie (NYSE: ABBV) today announced that data evaluating several investigational compounds in the company's oncology pipeline will be presented at the upcoming 2013 American Society of Clinical Oncology (ASCO) Annual Meeting, May 31 - June 4, Chicago. Data being presented include the results from two clinical trials evaluating the safety and...

2013-04-04 08:28:50

BOULDER, Colo., April 4, 2013 /PRNewswire/ -- Array BioPharma Inc. (NASDAQ: ARRY) today announced that results from two ongoing ARRY-520 clinical trials in multiple myeloma (MM) were presented at the 2013 International Myeloma Workshop in Kyoto, Japan. ARRY-520 is a potent, selective KSP inhibitor with a mechanism of action distinct from other drugs used to treat MM that continues to advance in clinical trials. (Logo: http://photos.prnewswire.com/prnh/20121029/LA02195LOGO) Results on the...

2013-04-02 10:47:08

Researchers at Mayo Clinic Cancer Center have developed new guidelines to treat recently diagnosed multiple myeloma patients who are not participating in clinical trials. The guidelines give physicians practical, easy to follow recommendations for providing initial therapy, stem cell transplant and maintenance therapy. The guidelines are published in the current issue of the journal Mayo Clinic Proceedings and represent a consensus opinion of hematologists at Mayo Clinic Cancer Center sites...